Ishikawa Akihisa, Tanaka Hiroki, Nakamura Satoshi, Kumada Hiroaki, Sakurai Yoshinori, Watanabe Kenichi, Yoshihashi Sachiko, Tanagami Yuki, Uritani Akira, Kiyanagi Yoshiaki
Research Group for Nuclear Sensing, Nuclear Science and Engineering Center, Japan Atomic Energy Agency, 2-4 Shirakata, Tokai-mura, Ibaraki 319-1195, Japan.
Department of Applied Energy, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8603, Japan.
J Radiat Res. 2024 Dec 3;65(6):765-775. doi: 10.1093/jrr/rrae076.
From the viewpoints of the advantage depths (ADs), peak tumor dose and skin dose, we evaluated the effect on the dose distribution of neutron beam properties, namely the ratio between thermal and epithermal neutron fluxes (thermal/epithermal ratio), fast neutron component and γ-ray component. Several parameter surveys were conducted with respect to the beam properties of neutron sources for boron neutron capture therapy assuming boronophenylalanine as the boron agent using our dose calculation tool, called SiDE. The ADs decreased by 3% at a thermal/epithermal ratio of 20-30% compared with the current recommendation of 5%. The skin dose increased with the increasing thermal/epithermal ratio, reaching a restricted value of 14 Gyeq at a thermal/epithermal ratio of 48%. The fast neutron component was modified using two different models, namely the 'linear model', in which the fast neutron intensity decreases log-linearly with the increasing neutron energy, and the 'moderator thickness (MT) model', in which the fast neutron component is varied by adjusting the MT in a virtual beam shaping assembly. Although a higher fast neutron component indicated a higher skin dose, the increment was <10% at a fast neutron component of <1 × 10-12 Gy cm2 for both models. Furthermore, in the MT model, the epithermal neutron intensity at a fast neutron component of 6.8 × 10-13 Gy cm2 was 41% higher compared with that of 2 × 10-13 Gy cm2. The γ-ray component also caused no significant disadvantages up to several times larger compared with the current recommendation.
从优势深度(ADs)、肿瘤峰值剂量和皮肤剂量的角度,我们评估了中子束特性对剂量分布的影响,即热中子通量与超热中子通量之比(热中子/超热中子比)、快中子成分和γ射线成分。使用我们称为SiDE的剂量计算工具,针对以硼代苯丙氨酸作为硼剂的硼中子俘获治疗的中子源束特性进行了几次参数调查。与当前5%的推荐值相比,当热中子/超热中子比为20%-30%时,ADs降低了3%。皮肤剂量随热中子/超热中子比的增加而增加,在热中子/超热中子比为48%时达到14 Gyeq的限值。使用两种不同的模型对快中子成分进行了修正,即“线性模型”(其中快中子强度随中子能量增加呈对数线性下降)和“慢化剂厚度(MT)模型”(其中通过在虚拟束整形组件中调整MT来改变快中子成分)。尽管较高的快中子成分表明皮肤剂量较高,但对于这两种模型,在快中子成分<1×10⁻¹² Gy cm²时,增量<10%。此外,在MT模型中,快中子成分6.8×10⁻¹³ Gy cm²时的超热中子强度比2×10⁻¹³ Gy cm²时高41%。与当前推荐值相比,γ射线成分在增大几倍的情况下也未造成明显不利影响。